BLI VS HRTX Stock Comparison

Performance

BLI
10/100

BLI returned -83.56% in the last 12 months. Based on the other stocks in it's sector with an average return of -31.49%, it's performance is below average giving it a grade of 10 of 100.

HRTX
10/100

HRTX returned -83.89% in the last 12 months. Based on SPY's performance of -21.12%, its performance is below average giving it a score of 10 of 100.

Forecast

BLI
75/100

5 analysts offer 12-month price forecasts for BLI. Together, they have an average target of 0, the most optimistic forecast put BLI at 0 within 12-months and the most pessimistic has BLI at 0.

HRTX

"Forecast" not found for HRTX

Sentiment

BLI
62/100

BLI had a bullish sentiment score of 62.13% across Twitter and StockTwits over the last 12 months. It had an average of 5.53 posts, 0.77 comments, and 1.49 likes per day.

HRTX
69/100

HRTX had a bullish sentiment score of 68.91% across Twitter and StockTwits over the last 12 months. It had an average of 12.30 posts, 7.19 comments, and 19.52 likes per day.

Technicals

BLI
11/100

BLI receieves a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

HRTX
11/100

HRTX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

BLI
10/100

BLI has missed earnings 7 times in the last 20 quarters.

HRTX
10/100

HRTX has missed earnings 8 times in the last 20 quarters.

Profit

BLI
10/100

Out of the last 10 quarters, BLI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

HRTX
10/100

Out of the last 20 quarters, HRTX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

BLI
42/100

BLI has had a lower than average amount of volatility over the last 12 months giving it a grade of 42 of 100.

HRTX
48/100

HRTX has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

Analyst Price Targets

BLI

"Analyst Price Targets" not found for BLI

HRTX
82/100

11 analysts offer 12-month price targets for HRTX. Together, they have an average target of 0, the most optimistic target put HRTX at 0 within 12-months and the most pessimistic has HRTX at 0.

All score calculations are broken down here to help you make more informed investing decisions

Berkeley Lights, Inc. Common Stock Summary

Nasdaq / BLI

Healthcare

Biotechnology

Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. Berkeley Lights, Inc. was incorporated in 2011 and is headquartered in Emeryville, California.

Heron Therapeutics, Inc. Summary

Nasdaq / HRTX

Healthcare

Biotechnology

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Power up your portfolio